Lakefront Biotherapeutics
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Henry O. Gosebruch
- Full Time Employees
- 452
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Schalienhoevedreef 20 T Mechelen Belgium 2800
- IPO Date
- Apr 14, 2005
- Website
- glpg.com
- Similar Companies
- Business
- Lakefront Biotherapeutics NV operates as a biopharmaceutical company focusing on oncology and immunology & inflammation. The company identifies, acquires, and advances promising therapeutic opportunities through a modality-agnostic asset selection approach and operational flexibility, aiming to deliver medicines with meaningful clinical impact for patients and value for shareholders. Headquarters and primary operations are in Europe, with activities extending to the United States, and the firm emphasizes deal making, capital deployment, and strategic partnerships to accelerate development across its pipeline. Main products and services: core development programs and platform capabilities across oncology and immunology/inflammation, including CAR-T product candidates manufactured at point-of-care, and small molecule or antibody therapies within its clinical pipeline; licensing, in-licensing, and collaboration arrangements to advance candidates; strategic advisory and portfolio management services to optimize asset selection, development paths, and value realization; commercialization planning and regulatory navigation support for late-stage assets and potential region-specific launches. Latest major company changes: enters new partnerships and strategic alliances to advance high-potential programs in oncology and immunology/inflammation; completes or pursues financing rounds and potential acquisitions to strengthen its pipeline and balance sheet; launches or expands product candidates and associated clinical trials (Phase 1/2 and Phase 2) in targeted indications; implements strategic shifts toward expanded geographic reach and more flexible manufacturing and development approaches; rebranding and corporate restructuring to reflect its updated focus and governance. Industry context and strategic focus: operates within the biopharmaceutical industry, with emphasis on oncology and immunology/inflammation therapeutic areas; targets mid- to late-stage development programs and opportunities with clear clinical proof-of-concept; pursues global partnerships, licensing agreements, and potential co-development arrangements to accelerate clinical milestones; maintains a multi-regional footprint across Europe and North America to support trial execution and regulatory submissions. Geographic and corporate structure: maintains headquarters in Europe with substantial activity in the United States and broader Europe; engages in subsidiary and affiliate structures as needed to manage collaborations, asset acquisitions, and development programs; aligns with parent or related entities in the Lakefront Biotherapeutics ecosystem as appropriate to strategic objectives. Founding year and headquarters: founded in the late 1990s with historical ties to European biopharmaceutical leadership; headquarters located in Europe, with a focus on Mechelen, Belgium, and expanded international operations. Subsidiaries and relationships: maintains multiple programs and potential subsidiary arrangements tied to its asset-focused strategy; leverages relationships with research institutions, contract development and manufacturing organizations, and strategic partners to support rapid progression of candidates through clinical milestones.
Company News
Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysis
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Acquisition of Own Shares
Acquisition of Own Shares
Acquisition of Own Shares
Acquisition of Own Shares
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Acquisition of Own Shares
Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value
Acquisition of Own Shares
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Acquisition of Own Shares
Acquisition of Own Shares
Lakefront Receives Transparency Notification from Bank of America
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Acquisition of Own Shares
Acquisition of Own Shares